---
figid: PMC3474103__bjr-85-682-g022
figlink: /pmc/articles/PMC3474103/figure/bjr-85-682-g022/
number: F22
caption: Diagram demonstrating the sites and mechanism of action of novel agents for
  the management of pancreatic endocrine neoplasm. The growth factor receptors when
  occupied by their respective growth factors (in an autocrine or paracrine manner)
  lead to autophosphorylation of the intracellular tyrosine kinase component of the
  receptor. This activates the mammalian target of rapamycin (mTOR) pathway (among
  others), ultimately promoting protein synthesis, cell cycle progression and cell
  survival. The pathway can be inhibited by monoclonal antibodies to growth factor
  receptors, tyrosine kinase inhibitors or downstream mTOR inhibitors.
pmcid: PMC3474103
papertitle: 'Pancreatic endocrine neoplasms: a current update on genetics and imaging.'
reftext: S Philips, et al. Br J Radiol. 2012 Jun;85(1014):682-696.
pmc_ranked_result_index: '19700'
pathway_score: 0.8724013
filename: bjr-85-682-g022.jpg
figtitle: Diagram demonstrating the sites and mechanism of action of novel agents
  for the management of pancreatic endocrine neoplasm
year: '2012'
organisms: Homo sapiens
ndex: 588a4b44-deb0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3474103__bjr-85-682-g022.html
  '@type': Dataset
  description: Diagram demonstrating the sites and mechanism of action of novel agents
    for the management of pancreatic endocrine neoplasm. The growth factor receptors
    when occupied by their respective growth factors (in an autocrine or paracrine
    manner) lead to autophosphorylation of the intracellular tyrosine kinase component
    of the receptor. This activates the mammalian target of rapamycin (mTOR) pathway
    (among others), ultimately promoting protein synthesis, cell cycle progression
    and cell survival. The pathway can be inhibited by monoclonal antibodies to growth
    factor receptors, tyrosine kinase inhibitors or downstream mTOR inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MTOR
  - RRAD
  - EGFR
  - MTTP
  - PDGFRB
  - RAF1
  - FLT4
  - KDR
  - PDGFRA
  - KIT
  - FLT1
  - Temsirolimus
  - Tyrosine
  - tyrosine
  - Rapamycin
  - Sirolimus
  - Cancer
genes:
- word: mTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: (RAD
  symbol: RAD
  source: hgnc_alias_symbol
  hgnc_symbol: RRAD
  entrez: '6236'
- word: (EGFR)
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: (Abl,
  symbol: ABL
  source: hgnc_alias_symbol
  hgnc_symbol: MTTP
  entrez: '4547'
- word: Sunitanib(VEGFR,PDGFR,c-Kit)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: Raf-1)
  symbol: RAF1
  source: hgnc_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: VEGFR)
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR)
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: Sunitanib(VEGFR,PDGFR,c-Kit)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: Sunitanib(VEGFR,PDGFR,c-Kit)
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: VEGFR)
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Tyrosine
  source: MESH
  identifier: D014443
- word: tyrosine
  source: MESH
  identifier: D014443
- word: Rapamycin
  source: MESH
  identifier: D020123
- word: Sirolimus
  source: MESH
  identifier: D020123
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC3474103__F22
redirect_from: /figures/PMC3474103__F22
figtype: Figure
---
